<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881112450781</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881112450781</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Hippocampal N-acetylaspartate and morning cortisol levels in drug-naive, first-episode patients with major depressive disorder: effects of treatment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Ying</given-names></name>
<xref ref-type="aff" rid="aff5-0269881112450781">*</xref>
<xref ref-type="aff" rid="aff1-0269881112450781">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jia</surname><given-names>Yanbin</given-names></name>
<xref ref-type="aff" rid="aff5-0269881112450781">*</xref>
<xref ref-type="aff" rid="aff2-0269881112450781">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Xinjian</given-names></name>
<xref ref-type="aff" rid="aff3-0269881112450781">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ling</surname><given-names>Xueying</given-names></name>
<xref ref-type="aff" rid="aff1-0269881112450781">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Sirun</given-names></name>
<xref ref-type="aff" rid="aff1-0269881112450781">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Xu</surname><given-names>Guiyun</given-names></name>
<xref ref-type="aff" rid="aff4-0269881112450781">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Huang</surname><given-names>Li</given-names></name>
<xref ref-type="aff" rid="aff1-0269881112450781">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0269881112450781"><label>1</label>Medical Imaging Center, First Affiliated Hospital of Jinan University, Guangzhou, China</aff>
<aff id="aff2-0269881112450781"><label>2</label>Department of Psychiatry, First Affiliated Hospital of Jinan University, Guangzhou, China</aff>
<aff id="aff3-0269881112450781"><label>3</label>Medical Imaging Center, Guangdong 999 Brain Hospital, Guangzhou, China</aff>
<aff id="aff4-0269881112450781"><label>4</label>Department of Psychiatry, Guangzhou Psychiatric Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, China</aff>
<aff id="aff5-0269881112450781"><label>*</label>These authors are first co-authors</aff>
<author-notes>
<corresp id="corresp1-0269881112450781">Li Huang, Medical Imaging Center, First Affiliated Hospital of Jinan University, Guangzhou 510630, China Email: <email>cjr.huangli@vip.163.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>11</issue>
<fpage>1463</fpage>
<lpage>1470</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>An excess of glucocorticoids has been associated with hippocampal pathology in major depressive disorder (MDD). However, the relationships between depression, hippocampal structure and function, and cortisol levels are unclear, and the effects of antidepressant treatment on the measures are not well studied. For this study, 26 first-episode, treatment-naive, non-late-life adult depressed patients and 13 healthy controls were enrolled. Subjects underwent proton magnetic resonance spectroscopy (<sup>1</sup>H MRS) to obtain metabolite levels from the bilateral hippocampus. Patients with MDD were treated with serotonergic–noradrenergic reuptake inhibitor duloxetine for 12 weeks. After the 12-week period, all subjects with MDD underwent <sup>1</sup>H MRS again. Morning serum cortisol levels also were measured both before and after antidepressant treatment. Comparison of baseline values indicated that there were no significant differences in any of the metabolite ratios (N-acetyl aspartate/creatine (NAA/Cr) and choline (Cho)/Cr) in the bilateral hippocampus. After treatment, NAA/Cr ratios increased significantly in the right hippocampus compared with pre-treatment values. There was no correlation between morning serum cortisol levels and bilateral hippocampal NAA/Cr or Cho/Cr in patients with MDD. These findings suggest that there are unaltered hippocampal metabolites in the early stage of MDD. Antidepressant treatment may affect hippocampal NAA levels in patients with MDD. In addition, the results do not support cortisol-mediated hippocampal neurotoxicity as the major etiological mechanism.</p>
</abstract>
<kwd-group>
<kwd>Major depression</kwd>
<kwd>antidepressants</kwd>
<kwd>cortisol</kwd>
<kwd>hippocampus</kwd>
<kwd>proton magnetic resonance spectroscopy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0269881112450781" sec-type="intro">
<title>Introduction</title>
<p>Major depressive disorder (MDD) is one of the most prevalent and life-threatening forms of psychiatric illness associated with significant disability and mortality. According to World Health Organization estimates, MDD was the fourth contributor to global burden of disease in 2000 and will rank second by 2020 (<xref ref-type="bibr" rid="bibr62-0269881112450781">World Health Organization, 2001</xref>). Despite extensive preclinical and clinical investigations, the mechanism of antidepressant action as well as the pathophysiology and etiology of depression are not completely understood (<xref ref-type="bibr" rid="bibr42-0269881112450781">Nestler et al., 2002</xref>).</p>
<p>Neuroimaging studies have implicated that the hippocampus may have a role in the pathophysiology of MDD. The hippocampus is involved in learning and memory, contextual fear conditioning, and neuroendocrine regulation, deficits which often accompany depression (<xref ref-type="bibr" rid="bibr48-0269881112450781">Ravnkilde et al., 2002</xref>). Previous structural magnetic resonance imaging (MRI) studies of patients with MDD have consistently shown bilateral and unilateral reductions in hippocampal volume (<xref ref-type="bibr" rid="bibr27-0269881112450781">Koolschijn et al., 2009</xref>; <xref ref-type="bibr" rid="bibr57-0269881112450781">Videbech and Ravnkilde, 2004</xref>). These findings have been paralleled by histopathological studies showing reduced neuronal cell size and neuropil (<xref ref-type="bibr" rid="bibr47-0269881112450781">Rajkowska, 2003</xref>; <xref ref-type="bibr" rid="bibr54-0269881112450781">Stockmeier et al., 2004</xref>). Functional imaging studies in MDD have also revealed increased cerebral blood flow (<xref ref-type="bibr" rid="bibr4-0269881112450781">Bellani et al., 2011</xref>; <xref ref-type="bibr" rid="bibr58-0269881112450781">Videbech et al., 2002</xref>) or decreased glucose metabolism (<xref ref-type="bibr" rid="bibr52-0269881112450781">Saxena et al., 2001</xref>) in the hippocampus, and that hippocampal metabolism was normalized after successful antidepressant treatment (<xref ref-type="bibr" rid="bibr4-0269881112450781">Bellani et al., 2011</xref>; <xref ref-type="bibr" rid="bibr26-0269881112450781">Kennedy et al., 2001</xref>).</p>
<p>Magnetic resonance spectroscopy (MRS) is a reliable non-invasive neuroimaging technique for the measurement of cerebral metabolites that reflect the metabolic integrity and density of neurons and glial cells. Typical compounds that can be measured using proton (<sup>1</sup>H) MRS include N-acetylaspartate (NAA), choline-containing compounds (Cho), myo-inositol (mI), creatine plus phosphocreatine (Cr), glutamate (Glu), and glutamate+glutamine (Glx). Several <sup>1</sup>H MRS studies of MDD have demonstrated biochemical or metabolic abnormalities in certain anatomical regions, such as increased levels of choline in the basal ganglia (<xref ref-type="bibr" rid="bibr59-0269881112450781">Vythilingam et al., 2003</xref>; <xref ref-type="bibr" rid="bibr64-0269881112450781">Yildiz-Yesiloglu and Ankerst, 2006</xref>) and the prefrontal cortex (<xref ref-type="bibr" rid="bibr19-0269881112450781">Farchione et al., 2002</xref>; <xref ref-type="bibr" rid="bibr29-0269881112450781">Kumar et al., 2002</xref>; <xref ref-type="bibr" rid="bibr53-0269881112450781">Steingard et al., 2000</xref>), decreased NAA in the caudate (<xref ref-type="bibr" rid="bibr59-0269881112450781">Vythilingam et al., 2003</xref>) and the dorsolateral prefrontal cortex (<xref ref-type="bibr" rid="bibr22-0269881112450781">Gruber et al., 2003</xref>; <xref ref-type="bibr" rid="bibr45-0269881112450781">Olvera et al., 2010</xref>), and decreased Glx/Glu (<xref ref-type="bibr" rid="bibr1-0269881112450781">Auer et al., 2000</xref>; <xref ref-type="bibr" rid="bibr40-0269881112450781">Mirza et al., 2004</xref>; <xref ref-type="bibr" rid="bibr64-0269881112450781">Yildiz-Yesiloglu and Ankerst, 2006</xref>) and ml (<xref ref-type="bibr" rid="bibr12-0269881112450781">Coupland et al., 2005</xref>; <xref ref-type="bibr" rid="bibr22-0269881112450781">Gruber et al., 2003</xref>) in the anterior cingulate. Furthermore, some studies found increased concentration of NAA, ml, Glx in the prefrontal cortex and occipital cortex of MDD patients with successful antidepressant treatment (<xref ref-type="bibr" rid="bibr4-0269881112450781">Bellani et al., 2011</xref>; <xref ref-type="bibr" rid="bibr21-0269881112450781">Gonul et al., 2006</xref>; <xref ref-type="bibr" rid="bibr25-0269881112450781">Kaymak et al., 2009</xref>; <xref ref-type="bibr" rid="bibr55-0269881112450781">Taylor et al., 2008</xref>). Unfortunately, few studies have examined the alterations in metabolites in the hippocampus of patients with MDD. In addition, studies usually recruited depressed subjects taking antidepressant medication, with chronic episodes, or late-life/geriatric MDD patients, thus their results might be biased because of the possible effects of medication or of brain degeneration due to aging. Therefore, to better understand the primary metabolic changes in the brain and antidepressant effects in patients with MDD, the aforementioned limitations need to be overcome in research.</p>
<p>Disturbed hypothalamus–pituitary–adrenal (HPA) axis function is a core feature of depression, which leads to excessive and prolonged hypercortisolemia (<xref ref-type="bibr" rid="bibr28-0269881112450781">Krishnan and Nestler, 2008</xref>; <xref ref-type="bibr" rid="bibr49-0269881112450781">Sala et al., 2004</xref>). High levels of glucocorticoids in animals, through the activation of glucocorticoid receptors, can reduce adult hippocampal neurogenesis (<xref ref-type="bibr" rid="bibr28-0269881112450781">Krishnan and Nestler, 2008</xref>), induce the retraction of hippocampal apical dendrites (<xref ref-type="bibr" rid="bibr36-0269881112450781">McLaughlin et al., 2007</xref>) and cause neuronal death or apoptosis in the hippocampus (<xref ref-type="bibr" rid="bibr13-0269881112450781">Crochemore et al., 2005</xref>; <xref ref-type="bibr" rid="bibr49-0269881112450781">Sala et al., 2004</xref>; <xref ref-type="bibr" rid="bibr51-0269881112450781">Sapolsky, 2000b</xref>). Antidepressant treatment appeared to normalize glucocorticoid levels (<xref ref-type="bibr" rid="bibr63-0269881112450781">Yau et al., 2002</xref>), to increase neurogenesis and dendritic branching in the adult rodent hippocampus (<xref ref-type="bibr" rid="bibr14-0269881112450781">Czeh et al., 2001</xref>; <xref ref-type="bibr" rid="bibr24-0269881112450781">Jacobs et al., 2000</xref>; <xref ref-type="bibr" rid="bibr33-0269881112450781">Malberg et al., 2000</xref>; <xref ref-type="bibr" rid="bibr35-0269881112450781">Manev et al., 2001</xref>), and to prevent changes in hippocampal neurons (<xref ref-type="bibr" rid="bibr32-0269881112450781">Magarinos et al., 1999</xref>). Although an influential hypothesis suggests that hypercortisolemia during depression may be important (<xref ref-type="bibr" rid="bibr50-0269881112450781">Sapolsky, 2000a</xref>), glucocorticoid-induced neuronal damage of the hippocampus has not yet been completely confirmed in human postmortem brain tissue from depressed patients. In addition, few previous neuroimaging investigators have examined HPA axis function in relation to hippocampal changes. Two structural MRI studies showed reduced hippocampal volume that might be associated with the increased cortisol concentration in MDD (<xref ref-type="bibr" rid="bibr2-0269881112450781">Axelson et al., 1993</xref>; <xref ref-type="bibr" rid="bibr31-0269881112450781">Lupien et al., 1998</xref>). However, there are no studies using MRS to measure the relationship between the metabolite levels of the hippocampus and peripheral glucocorticoids in depressive patients.</p>
<p>In the present study, metabolic characteristics in the bilateral hippocampus of first-episode, treatment-naive, non-late-life adult patients with MDD and healthy controls were investigated with <sup>1</sup>H-MRS. The interrelationships between hippocampal metabolites and cortisol levels were evaluated specifically. The effects of antidepressant treatment on hippocampal metabolites and cortisol status were also evaluated. We hypothesized that hippocampal metabolic abnormalities such as NAA/Cr, Cho/Cr occurred at the early stage of depression, and these metabolites were normalized after successful antidepressant treatment. We also hypothesized that cortisol levels would correlate inversely with hippocampal metabolites, particularly NAA levels.</p>
</sec>
<sec id="section2-0269881112450781" sec-type="methods">
<title>Methods</title>
<sec id="section3-0269881112450781">
<title>Participants</title>
<p>In total, 26 out- or in-patients with MDD were recruited from the psychiatry department of First Affiliated Hospital of Jinan University, Guangzhou, China. The age of all participants was restricted to 18–45 years to reduce the potential effects of aging and vascular disease. All depressed participants met DSM-IV criteria for MDD according to the diagnostic assessment by the Structured Clinical Interview for DSM-IV-Patient Edition (SCID-P) and had scores of 18 or greater on the 17-item Hamilton Depression Rating Scale (HAMD). Neurological or organic disorders were determined according to personal histories and complete physical examinations. Specific inclusion criteria for patients were that they were treatment-naive and experiencing their first episode of MDD. Exclusion criteria included the presence of (1) other Axis I psychiatric disorders and symptoms, (2) a history of the use of any psychotropic medication, psychotherapy or electroconvulsive therapy (ECT), (3) a history of organic brain disorder, neurological disorders, or cardiovascular diseases, (4) alcohol/substance abuse within 6 months before study entry, and (5) pregnancy or any physical illness demonstrated by personal history, or clinical or laboratory examinations. After conducting MRS and cortisol measurement, all patients with MDD were treated with the serotonergic–noradrenergic reuptake inhibitor duloxetine (60–120 mg/day). Some 12 weeks later all patients underwent a second brain MRS scan, cortisol measurements and HAMD examination.</p>
<p>Thirteen healthy control subjects were also recruited via local advertisements. They were carefully screened through a diagnostic interview, the Structured Clinical Interview for DSM-IV Nonpatient Edition (SCID-NP), to rule out the presence of current or past psychiatric illness. Further exclusion criteria for healthy controls were any history of psychiatric illness in first-degree relatives, and current or past significant medical or neurological illness.</p>
<p>All participants were right-handed. They were submitted to MRI scanning and biological investigations within 48 h of initial contact. The participants were instructed to refrain from physical exercise and large meals at least 90 min before measurement of the serum cortisol. In addition, participants were excluded if they had exposure to oral or intravenous steroids, or any MRI contraindications. The study was approved by the Ethics Committee of First Affiliated Hospital of Jinan University, China. All subjects signed a written informed consent form after a full written and verbal explanation of the study.</p>
</sec>
<sec id="section4-0269881112450781">
<title>Image acquisition</title>
<p>Both MRI and <sup>1</sup>H MRS were performed on a clinical 1.5-Tesla GE Signa MR system (General Electric, Milwaukee, WI, USA) with a conventional gradient system. A standard eight-channel head coil was used for radiofrequency transmission and reception of the MR signal. The subject lay in the supine position; the nasion served as a landmark. Ear plugs and foam pads were used to reduce noise and minimize head motion. Routine axial T<sub>1</sub>-weighted fluid attenuation inversion recovery (T<sub>1</sub>Flair) (repetition time (TR)=1800 ms, echo-time (TE) = 24 ms) and fast-spin echo T<sub>2</sub>-weighted MR images (TR=4500 ms, TE=120 ms) were obtained to confirm the absence of any structural and signal abnormality of the brain.</p>
<p>Axial T<sub>2</sub>-weighted MR images were used for anatomical localization (TR=5000 ms, TE=113 ms, slice thickness=5 mm without a gap). For MRS studies, the volume of interest (VOI) was chosen in normal-appearing hippocampal tissue at the midbrain level. The VOI was placed in a uniform manner by the same investigator and included 55 voxels. Each voxel had nominal dimensions of 7.5×7.5×10 mm<sup>3</sup>. <xref ref-type="fig" rid="fig1-0269881112450781">Figure 1</xref> shows the VOI location in an MRI scan of the brain. Subsequent repositioning of the VOI after the 12-week period was done by careful three-dimensional visual comparison with the VOI placement for the first session, so that an uncertainty of up to 1.5 mm in either dimension was not exceeded. Two-dimensional (2D) multi-voxel <sup>1</sup>H MRS was acquired using a point resolved spectroscopy sequence (PRESS) with water suppression by a chemical shift selective saturation (CHESS) pulse. The acquisition parameters were the following: TR=1000 ms; TE=144 ms; numbers of excitation=1; spatial matrix=18×18; field of view=240×240 mm; slice thickness=10 mm. Additional saturation bands were placed outside the VOI to minimize lipid contamination from the skull and scalp. Before the spectroscopic acquisitions shimming of magnetic homogeneity was done. Usually, a line width (FWHM) of 7–9 Hz was achieved on the water resonance of the VOI. As a general quality standard, spectra with a line width above 10 Hz or water suppression above 98% were excluded. Total acquisition time for <sup>1</sup>H MRS sequence was 5 min and 28 s.</p>
<fig id="fig1-0269881112450781" position="float">
<label>Figure 1.</label>
<caption>
<p>Magnetic resonance imaging scan of healthy control subject showing location of magnetic resonance spectroscopy (MRS) volume of interest (VOI) placed in the bilateral hippocampus. The large white boxes represent the VOIs for MRS acquisition (predefined brain regions), and small white boxes (1, 2) depict the individual VOIs for spectral analysis.</p>
</caption>
<graphic xlink:href="10.1177_0269881112450781-fig1.tif"/>
</fig>
<p>The analyses of the spectral dataset were performed with the manufacturer-supplied software package program of the MR system (GE Advantage Workstation: AW4.2_07). Voxels were repositioned in predefined brain areas, which were localized at left and right hippocampal head (<xref ref-type="fig" rid="fig1-0269881112450781">Figure 1</xref>). Each spectrum was evaluated for the peak area of Cho at 3.22 ppm, Cr at 3.03 ppm, and NAA at 2.02 ppm (<xref ref-type="fig" rid="fig2-0269881112450781">Figure 2</xref>). The values of the NAA/Cr, Cho/Cr ratios were used for the analyses. Voxel placements for spectroscopy and all data analysis were carried out by a trained radiologist who was blind to each subject’s diagnosis.</p>
<fig id="fig2-0269881112450781" position="float">
<label>Figure 2.</label>
<caption>
<p>Proton magnetic resonance spectra in the right hippocampus in a 27-year-old male patient with major depression.</p>
<p>Note: Cho, choline; Cr, creatine; NAA, N-acetylaspartate</p>
</caption>
<graphic xlink:href="10.1177_0269881112450781-fig2.tif"/>
</fig>
</sec>
<sec id="section5-0269881112450781">
<title>Hormone measurement</title>
<p>The participant was asked to lie on a bed in the supine position. A needle was inserted into an antecubital vein for blood sampling at 8:00–9:00 AM (approximately 20 min after MRI scanning on days when scanning and cortisol level assays occurred on the same study day). Serum or plasma was prepared by centrifugation and the samples stored at -70°C to -80°C. The serum cortisol level was determined using a commercially available radioimmunometric assay kit.</p>
</sec>
<sec id="section6-0269881112450781">
<title>Statistical analysis</title>
<p>All data analysis was performed using SPSS for Windows software, version 15.0 (SPSS Inc., Chicago, III, USA) and two-tailed significance level was set at <italic>p</italic>&lt;0.05. Independent samples <italic>t</italic>-test and χ<sup>2</sup> test were used to compare demographic data between the MDD and healthy group. Independent samples <italic>t</italic>-test was used to compare metabolite ratios and cortisol levels between patient and healthy control groups. Metabolite ratios, cortisol levels and HAMD scores of patients before and after antidepressant treatment were compared with paired samples <italic>t</italic>-test. Pearson’s correlation coefficients were used to correlate cortisol levels and clinical variables within the measured metabolite levels.</p>
</sec></sec>
<sec id="section7-0269881112450781" sec-type="results">
<title>Results</title>
<p><xref ref-type="table" rid="table1-0269881112450781">Table 1</xref> shows the demographic and clinical data of all study participants. We included 26 MDD patients (11 men, 15 women) with a mean age of 32.12±8.38 (range 20–45) years and13 healthy controls (six men, seven women) with a mean age of 29.69±8.45 (18–45) years. The mean number of education years was 10.40±3.20 (5–16) years for patients and 12.60±2.80 (7–16) years for controls. There were no significant differences in sex, age, and educational status between the MDD group and the healthy control group. Among patients, the mean duration of illness was 2.47±0.78 months. HAMD mean score at baseline was 25.71±4.91 (19–35) and this mean score was 5.50 ± 3.38 (2–15) at 12 weeks of treatment. The HAMD scores decreased significantly (<italic>p</italic>&lt;0.001) after treatment.</p>
<table-wrap id="table1-0269881112450781" position="float">
<label>Table 1.</label>
<caption>
<p>Demographic and clinical data of subjects</p>
</caption>
<graphic alternate-form-of="table1-0269881112450781" xlink:href="10.1177_0269881112450781-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">MDD patients</th>
<th align="left">Healthy controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects</td>
<td>26</td>
<td>13</td>
</tr>
<tr>
<td>Age (years)</td>
<td>32.12 (8.38)</td>
<td>29.69 (8.45)</td>
</tr>
<tr>
<td>Age range (years)</td>
<td>20–45</td>
<td>18–45</td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td>11/15</td>
<td>6/7</td>
</tr>
<tr>
<td>Education (years)</td>
<td>10.40 (3.20)</td>
<td>12.60 (2.80)</td>
</tr>
<tr>
<td>Duration of illness (months)</td>
<td>2.47 (0.78)</td>
<td/>
</tr>
<tr>
<td>17-item HAMD score (points)</td>
<td/>
<td/>
</tr>
<tr>
<td>Baseline</td>
<td>25.71±4.91</td>
<td/>
</tr>
<tr>
<td>After treatment</td>
<td>5.50±3.38</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269881112450781">
<p>Standard deviations are in parentheses. MDD: major depressive disorder; HAMD: Hamilton Depression Rating Scale</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>None of the metabolite ratios (NAA/Cr and Cho/Cr) measured on <sup>1</sup>H-MRS in the bilateral hippocampus differed between patients and healthy controls. After the treatment, NAA/Cr ratios increased significantly (<italic>t</italic>=-3.25, <italic>p</italic>=0.003) in the right hippocampus compared with pre-treatment values (<xref ref-type="table" rid="table2-0269881112450781">Table 2</xref>). There was no significant difference between pre- and post-treatment NAA/Cr in the left and Cho/Cr ratios in the bilateral hippocampus. Moreover, there was no significant difference in the metabolite ratios between post-treatment patients and healthy controls. No correlation between metabolite ratios and Hamilton Depression Rating Scale scores before and after antidepressant treatment was observed.</p>
<table-wrap id="table2-0269881112450781" position="float">
<label>Table 2.</label>
<caption>
<p>Metabolite ratios in the hippocampus regions in MDD patients and in healthy controls</p>
</caption>
<graphic alternate-form-of="table2-0269881112450781" xlink:href="10.1177_0269881112450781-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left" colspan="2">Left hippocampus<hr/></th>
<th align="left" colspan="2">Right hippocampus<hr/></th>
</tr>
<tr>
<th/>
<th align="left">NAA/Cr</th>
<th align="left">Cho/Cr</th>
<th align="left">NAA/Cr</th>
<th align="left">Cho/Cr</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">Baseline comparison</td>
</tr>
<tr>
<td>Patients (<italic>n</italic>=26)</td>
<td>1.36 (0. 24)</td>
<td>1.32 (0.30)</td>
<td>1.42 (0.33)</td>
<td>1.35 (0.43)</td>
</tr>
<tr>
<td>Controls (<italic>n</italic>=13)</td>
<td>1.53 (0.23)</td>
<td>1.17 (0.18)</td>
<td>1.44 (0.33)</td>
<td>1.20 (0.14)</td>
</tr>
<tr>
<td><italic>t</italic> value</td>
<td>–1.82</td>
<td>1.18</td>
<td>–1.01</td>
<td>1.30</td>
</tr>
<tr>
<td><italic>df</italic> value</td>
<td>37</td>
<td>37</td>
<td>37</td>
<td>37</td>
</tr>
<tr>
<td><italic>p</italic> value</td>
<td>0.085</td>
<td>0.248</td>
<td>0.318</td>
<td>0.202</td>
</tr>
<tr>
<td colspan="5">Follow–up comparison</td>
</tr>
<tr>
<td>Pre-treatment patients (<italic>n</italic>=26)</td>
<td>1.36 (0. 24)</td>
<td>1.32 (0.30)</td>
<td>1.42 (0.33)</td>
<td>1.35 (0.43)</td>
</tr>
<tr>
<td>Post-treatment patients (<italic>n</italic>=26)</td>
<td>1.39 (0.32)</td>
<td>1.35 (0.46)</td>
<td>1.63 (0.36) <xref ref-type="table-fn" rid="table-fn2-0269881112450781">*</xref></td>
<td>1.38 (0.29)</td>
</tr>
<tr>
<td><italic>t</italic> value</td>
<td>–0.46</td>
<td>–0.97</td>
<td>–3.25</td>
<td>0.01</td>
</tr>
<tr>
<td><italic>df</italic> value</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td><italic>p</italic> value</td>
<td>0.650</td>
<td>0.340</td>
<td>0.003</td>
<td>0.998</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0269881112450781">
<p>Standard deviations are in parentheses. MDD: major depressive disorder; 1H MRS: proton magnetic resonance spectroscopy, NAA/Cr: N–acetylaspartate/ creatine; Cho/Cr: choline/ creatine. *The difference between pre–treatment MDD and post–treatment MDD (<italic>p</italic>&lt;0.05)</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Depressed patients did not have significantly higher serum cortisol levels compared with healthy control subjects (398.75±133.24 nmol/L vs. 342.44±66.54 nmol/L; <italic>F</italic>=2.52, <italic>p</italic>=0.243). There was no significant difference between pre- and post-treatment serum cortisol levels (398.75±133.24 nmol/L vs. 336.02±137.64 nmol/L; <italic>t</italic>=0.935, <italic>p</italic>=0.372). Moreover, we found that cortisol levels between 8:00 and 9:00 in the morning were not associated with bilateral hippocampal NAA/Cr (left: <italic>r</italic>=0.286, <italic>p</italic>=0.393; right: r=0.404, <italic>p</italic>=0.218) or Cho/Cr (left: <italic>r</italic>=0.270, <italic>p</italic>=0.421; right: <italic>r</italic>=0.423, <italic>p</italic>=0.195) in MDD patients.</p>
</sec>
<sec id="section8-0269881112450781" sec-type="discussion">
<title>Discussion</title>
<p>To our knowledge, this is the first study to demonstrate metabolic changes of the bilateral hippocampus and serum cortisol levels in first-episode treatment-naive non-late-life adult patients with MDD. In the present study, there was no significant difference in the major metabolite ratios (NAA/Cr and Cho/Cr) of the bilateral hippocampus between untreated MDD patients and healthy controls. However, after the treatment, NAA/Cr ratios increased significantly in the right hippocampus compared with pre-treatment values. In addition, cortisol levels did not show a significant relationship with hippocampal neurometabolites.</p>
<p>In this study, no abnormal NAA and Cho levels were observed in the bilateral hippocampus in patients with MDD, which is in agreement with the majority of publications (<xref ref-type="bibr" rid="bibr6-0269881112450781">Block et al., 2009</xref>; <xref ref-type="bibr" rid="bibr38-0269881112450781">Michael et al., 2003</xref>; <xref ref-type="bibr" rid="bibr64-0269881112450781">Yildiz-Yesiloglu and Ankerst, 2006</xref>). However, several <sup>1</sup>H-MRS studies found changed hippocampal metabolites in depressed patients (<xref ref-type="bibr" rid="bibr18-0269881112450781">Ende et al., 2000</xref>; <xref ref-type="bibr" rid="bibr37-0269881112450781">Mervaala et al., 2000</xref>; <xref ref-type="bibr" rid="bibr39-0269881112450781">Milne et al., 2009</xref>). These divergent results may be explained by differences in patient characteristics, such as age, sex, handedness, age at illness onset, medication exposures, illness duration, number of acute episodes and severity of illness. Alternatively, these MRS investigations used various MRS acquisition sequences and methods for metabolite quantification, which may also have partly accounted for discrepancies. In the present study, we studied homogeneous first-episode, treatment-naive and non-late-life adult MDD patients to eliminate potential confounding factors, which is considerable strength of this study. Spectra were acquired using a 2D multi-voxel method. A multi-voxel technique has the advantage of obtaining multiple spectra simultaneously, therefore evaluating multiple regions of interest during one measurement. Smaller voxels result in less contamination from neighboring tissues.</p>
<p>Our principal finding was that antidepressant treatment increased the NAA/Cr ratios in the right hippocampus in depressed patients who had responded to treatment. NAA is the second most abundant amino acid in the central nervous system and it is localized mostly in neurons, oligodendrocyte precursors and mature oligodendrocytes. It has been proposed that NAA may be a marker of neuronal/axonal tissue that includes functional aspects of formation and/or maintenance of myelin, dendritic and synaptic proliferation (<xref ref-type="bibr" rid="bibr5-0269881112450781">Bhakoo and Pearce, 2000</xref>; <xref ref-type="bibr" rid="bibr56-0269881112450781">Urenjak et al., 1993</xref>). In the cross-sectional group comparison of untreated MDD patients and healthy controls, hippocampal NAA was not reduced in MDD patients, which is consistent with previous reports (<xref ref-type="bibr" rid="bibr6-0269881112450781">Block et al., 2009</xref>; <xref ref-type="bibr" rid="bibr8-0269881112450781">Capizzano et al., 2007</xref>; <xref ref-type="bibr" rid="bibr18-0269881112450781">Ende et al., 2000</xref>; <xref ref-type="bibr" rid="bibr38-0269881112450781">Michael et al., 2003</xref>; <xref ref-type="bibr" rid="bibr64-0269881112450781">Yildiz-Yesiloglu and Ankerst, 2006</xref>). However, <xref ref-type="bibr" rid="bibr23-0269881112450781">Huang and colleagues (2010)</xref> found that NAA/Cr ratios in the hippocampus were lower in drug-naive post-stroke depression patients than in controls, and these levels may increase with successful antidepressant treatment. Furthermore, studies demonstrated that NAA reductions are reversible, suggesting that it is sensitive to processes affecting neuronal function (<xref ref-type="bibr" rid="bibr41-0269881112450781">Moore et al., 2000</xref>). Despite the lack of differences at baseline in the present study, increases in the NAA/Cr ratios after treatment might also indicate the influence of antidepressant treatment on the possible potential damage in the hippocampal neuronal/axonal tissue (<xref ref-type="bibr" rid="bibr51-0269881112450781">Sapolsky, 2000b</xref>) Previous MRS studies reported that antidepressant strategies, for example, selective serotonin reuptake inhibitors (SSRIs) (<xref ref-type="bibr" rid="bibr21-0269881112450781">Gonul et al., 2006</xref>; <xref ref-type="bibr" rid="bibr23-0269881112450781">Huang et al., 2010</xref>), lithium (<xref ref-type="bibr" rid="bibr11-0269881112450781">Colla et al., 2009</xref>; <xref ref-type="bibr" rid="bibr41-0269881112450781">Moore et al., 2000</xref>), or ECT (<xref ref-type="bibr" rid="bibr38-0269881112450781">Michael et al., 2003</xref>), increased NAA levels in depressed patients who had responded to treatment. These findings are in agreement with our results suggesting an improvement of neuronal functionality and viability in the hippocampus. Moreover, the protective effect of antidepressants on hippocampal neurons evidenced by NAA concentrations has been demonstrated in animal studies (<xref ref-type="bibr" rid="bibr14-0269881112450781">Czeh et al., 2001</xref>).</p>
<p>Some volumetric MRI studies reported that continuous antidepressant treatment might contribute to subtle increases of hippocampal volumes, which is often most pronounced in the right hippocampus (<xref ref-type="bibr" rid="bibr20-0269881112450781">Frodl et al., 2008</xref>; <xref ref-type="bibr" rid="bibr34-0269881112450781">Malykhin et al., 2010</xref>). A recent postmortem study reported that MDD patients who took drug treatment had more neural progenitor cells and dividing cells in the dentate gyrus than untreated MDD patients and controls (<xref ref-type="bibr" rid="bibr7-0269881112450781">Boldrini et al., 2009</xref>). Preclinical studies also demonstrated that antidepressant therapy promoted newborn cell proliferation (<xref ref-type="bibr" rid="bibr35-0269881112450781">Manev et al., 2001</xref>; <xref ref-type="bibr" rid="bibr61-0269881112450781">Wang et al., 2008</xref>), survival and neurogenesis (<xref ref-type="bibr" rid="bibr33-0269881112450781">Malberg et al., 2000</xref>; <xref ref-type="bibr" rid="bibr46-0269881112450781">Perera et al., 2007</xref>; <xref ref-type="bibr" rid="bibr61-0269881112450781">Wang et al., 2008</xref>) in the dentate gyrus of rodents and nonhuman primates. In addition, recent data suggested that antidepressants increased neurotrophic factor expression, in particular brain-derived neurotrophic factor, which is hypothesized to contribute significantly to neurogenesis (<xref ref-type="bibr" rid="bibr3-0269881112450781">Banasr et al., 2011</xref>). Therefore, increased NAA levels with successful antidepressant treatment in this study might result from increased right hippocampal neurogenesis. In general, the right rather than left hippocampus appears more widely associated with emotion. Alternatively, our results also suggest that future MRS studies of the hippocampus in MDD should control for treatment effects on hippocampal neurometabolites.</p>
<p>Cho is an essential precursor of the neurotransmitter acetylcholine and the membrane lipids phosphatidylcholine and sphingomyelin, reflecting membrane turnover and cell proliferation (<xref ref-type="bibr" rid="bibr30-0269881112450781">Kusumakar et al., 2001</xref>). Reports of differences in hippocampal Cho levels in MDD have been mixed, with reports of increased (<xref ref-type="bibr" rid="bibr23-0269881112450781">Huang et al., 2010</xref>; <xref ref-type="bibr" rid="bibr37-0269881112450781">Mervaala et al., 2000</xref>; <xref ref-type="bibr" rid="bibr39-0269881112450781">Milne et al., 2009</xref>), decreased (<xref ref-type="bibr" rid="bibr18-0269881112450781">Ende et al., 2000</xref>, <xref ref-type="bibr" rid="bibr17-0269881112450781">2007</xref>), and unchanged Cho (<xref ref-type="bibr" rid="bibr6-0269881112450781">Block et al., 2009</xref>; <xref ref-type="bibr" rid="bibr38-0269881112450781">Michael et al., 2003</xref>; <xref ref-type="bibr" rid="bibr64-0269881112450781">Yildiz-Yesiloglu and Ankerst, 2006</xref>). On the whole, studies of more severely depressed patients are more likely to demonstrate abnormalities in hippocampal Cho levels, such as in subjects with multiple depressive episodes (<xref ref-type="bibr" rid="bibr18-0269881112450781">Ende et al., 2000</xref>; <xref ref-type="bibr" rid="bibr39-0269881112450781">Milne et al., 2009</xref>) and treatment-resistant depression (<xref ref-type="bibr" rid="bibr37-0269881112450781">Mervaala et al., 2000</xref>). In contrast to these studies, we did not observe abnormal hippocampal Cho/Cr ratios in patients with MDD. Consistent with our findings, <xref ref-type="bibr" rid="bibr39-0269881112450781">Milne and colleagues (2009)</xref> also failed to observe a significant difference in left hippocampus absolute Cho values in their patients presenting for first treatment of a depressive episode, although they did not examine ratios. Furthermore, structural MRI studies in MDD found no differences in hippocampal volumes between first-episode MDD patients and healthy controls, whereas reduced hippocampal volumes were found in their more chronic, severely and recurrently affected counterparts (<xref ref-type="bibr" rid="bibr15-0269881112450781">Eker and Gonul, 2010</xref>; <xref ref-type="bibr" rid="bibr16-0269881112450781">Eker et al., 2010</xref>). Thus, the present findings of no change in neurometabolites may at least partly stem from the relative young age range (20–45 years) of the patients and the timing of imaging, which was done at the first episode, and the very short duration of the study (&lt;3 months). In addition, it should be noted that <xref ref-type="bibr" rid="bibr39-0269881112450781">Milne et al. (2009)</xref> and <xref ref-type="bibr" rid="bibr6-0269881112450781">Block et al. (2009)</xref> showed in the hippocampus of depressed patients, respectively, abnormally increased mI levels and decreased Glx/Cr, Glu/Cr metabolite ratios. In our study, we did not include values for these smaller metabolites as they were not reliably and accurately quantified by our post-processing procedure. Therefore, we cannot rule out the possibility that mI or Glx concentrations within the hippocampus differed between patients and controls.</p>
<p>To our knowledge, this is the first study to assess the relationship between glucocorticoid levels and hippocampal neurometabolites in MDD. However, levels of morning serum cortisol did not show a significant relationship with hippocampal metabolites, especially NAA concentrations. Therefore, this did not provide support for the glucocorticoid toxicity hypothesis of hippocampal neuronal damage in depression. <xref ref-type="bibr" rid="bibr11-0269881112450781">Colla and colleagues (2009)</xref> found negative correlations between diurnal cortisol levels and hippocampal NAA concentrations in remitted bipolar I patients, whereas <xref ref-type="bibr" rid="bibr43-0269881112450781">Neylan and colleagues (2003)</xref> reported that saliva cortisol levels were positively correlated with hippocampal NAA in patients with posttraumatic stress disorder. In contrast, volumetric studies revealed cortisol levels were not related to hippocampal volume in MDD patients (<xref ref-type="bibr" rid="bibr10-0269881112450781">Colla et al., 2007</xref>; <xref ref-type="bibr" rid="bibr44-0269881112450781">O’Brien et al., 2004</xref>; <xref ref-type="bibr" rid="bibr60-0269881112450781">Vythilingam et al., 2004</xref>), which supports our finding of no relationship between cortisol levels and hippocampal NAA. The absence of hypercortisolemia in our patients may be an important factor in our failure to observe such relationships. In addition, more recent studies suggested that hypercortisolemia is almost exclusively a feature of very severe depressive episodes, such as are observed in an in-patient setting or accompanied by psychotic symptoms (for example, hallucinations and delusions) in which glucocorticoid antagonists show some therapeutic efficacy (<xref ref-type="bibr" rid="bibr55-0269881112450781">Taylor et al., 2008</xref>).</p>
<p>However, the findings of the present study should be viewed with caution due to a few potential limitations. First, the sample size is small and the results are not corrected for multiple comparisons. Thus, these data serve as hypothesis-generating data, which require confirmation. Second, a minority of subjects had a coexisting adjustment disorder; the lack of specific criteria for adjustment disorder may be responsible for some of the difficulties in diagnosing this disorder when compared with other depressive disorder diagnoses, especially mild and moderate depressive episode (<xref ref-type="bibr" rid="bibr9-0269881112450781">Casey et al., 2006</xref>). Third, we used a ratio rather than an absolute quantification of metabolites. The Cr level has been used as an internal reference for the quantification of other metabolites. However, some studies shows the Cr level in the brain may not be absolutely stable (<xref ref-type="bibr" rid="bibr22-0269881112450781">Gruber et al., 2003</xref>), which may affect the results. Fourth, the lack of a placebo arm and randomization makes it difficult to tease apart whether the results were related directly to the antidepressant treatment or as a function of non-specific clinical improvement over time. Last, serum cortisol was collected at a single time point in the morning, which was not enough to investigate the HPA axis activity. The relationship between the HPA axis and hippocampal metabolites in MDD should be explored in the future studies. For instance, dexamethasone suppression tests and diurnal or 24-h cortisol levels should be evaluated.</p>
<p>In conclusion, the present study reported unaltered levels of hippocampal metabolites in the early stage of MDD. However, we found that antidepressant use may affect hippocampal NAA levels in patients with MDD. In addition, our results do not support cortisol-mediated hippocampal neurotoxicity as the major etiological mechanism. Future longitudinal neuroimaging, biochemical and neuropsychological studies, with a larger patient sample size, are warranted to confirm these preliminary findings and to better characterize the relevance of neurochemical abnormalities in the pathophysiology of MDD patients.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>Funding for this study was provided by Guangdong Province of major science and technology projects (no.2011A080502014) and the Fundamental Research Funds for the Central Universities (no. 21612432). The funding source had no further role in study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>The authors declare that they have no conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Auer</surname><given-names>DP</given-names></name>
<name><surname>Pütz</surname><given-names>B</given-names></name>
<name><surname>Kraft</surname><given-names>E</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study</article-title>. <source>Biol Psychiatry</source> <volume>47</volume>: <fpage>305</fpage>–<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr2-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Axelson</surname><given-names>DA</given-names></name>
<name><surname>Doraiswamy</surname><given-names>PM</given-names></name>
<name><surname>McDonald</surname><given-names>WM</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Hypercortisolemia and hippocampal changes in depression</article-title>. <source>Psychiatry Res</source> <volume>47</volume>: <fpage>163</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr3-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Banasr</surname><given-names>M</given-names></name>
<name><surname>Dwyer</surname><given-names>JM</given-names></name>
<name><surname>Duman</surname><given-names>RS</given-names></name>
</person-group> (<year>2011</year>) <article-title>Cell atrophy and loss in depression: reversal by antidepressant treatment</article-title>. <source>Curr Opin Cell Biol</source> <volume>23</volume>: <fpage>730</fpage>–<lpage>737</lpage>.</citation>
</ref>
<ref id="bibr4-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bellani</surname><given-names>M</given-names></name>
<name><surname>Dusi</surname><given-names>N</given-names></name>
<name><surname>Yeh</surname><given-names>PH</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>The effects of antidepressants on human brain as detected by imaging studies. Focus on major depression</article-title>. <source>Progr Neuropsychopharmacol Biol Psychiatry</source> <volume>35</volume>: <fpage>1544</fpage>–<lpage>1552</lpage>.</citation>
</ref>
<ref id="bibr5-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhakoo</surname><given-names>KK</given-names></name>
<name><surname>Pearce</surname><given-names>D</given-names></name>
</person-group> (<year>2000</year>) <article-title>In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo</article-title>. <source>J Neurochem</source> <volume>74</volume>: <fpage>254</fpage>–<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr6-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Block</surname><given-names>W</given-names></name>
<name><surname>Traber</surname><given-names>F</given-names></name>
<name><surname>von Widdern</surname><given-names>O</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response</article-title>. <source>Int J Neuropsychopharmacol</source> <volume>12</volume>: <fpage>415</fpage>–<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr7-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boldrini</surname><given-names>M</given-names></name>
<name><surname>Underwood</surname><given-names>MD</given-names></name>
<name><surname>Hen</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Antidepressants increase neural progenitor cells in the human hippocampus</article-title>. <source>Neuropsychopharmacology</source> <volume>34</volume>: <fpage>2376</fpage>–<lpage>2389</lpage>.</citation>
</ref>
<ref id="bibr8-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Capizzano</surname><given-names>AA</given-names></name>
<name><surname>Jorge</surname><given-names>RE</given-names></name>
<name><surname>Acion</surname><given-names>LC</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>In vivo proton magnetic resonance spectroscopy in patients with mood disorders: A technically oriented review</article-title>. <source>J Magn Reson Imaging</source> <volume>26</volume>: <fpage>1378</fpage>–<lpage>1389</lpage>.</citation>
</ref>
<ref id="bibr9-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Casey</surname><given-names>P</given-names></name>
<name><surname>Maracy</surname><given-names>M</given-names></name>
<name><surname>Kelly</surname><given-names>BD</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Can adjustment disorder and depressive episode be distinguished? Results from ODIN</article-title>. <source>J Affect Disord</source> <volume>92</volume>: <fpage>291</fpage>–<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr10-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colla</surname><given-names>M</given-names></name>
<name><surname>Kronenberg</surname><given-names>G</given-names></name>
<name><surname>Deuschle</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Hippocampal volume reduction and HPA-system activity in major depression</article-title>. <source>J Psychiatr Res</source> <volume>41</volume>: <fpage>553</fpage>–<lpage>560</lpage>.</citation>
</ref>
<ref id="bibr11-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colla</surname><given-names>M</given-names></name>
<name><surname>Schubert</surname><given-names>F</given-names></name>
<name><surname>Bubner</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Glutamate as a spectroscopic marker of hippocampal structural plasticity is elevated in long-term euthymic bipolar patients on chronic lithium therapy and correlates inversely with diurnal cortisol</article-title>. <source>Mol Psychiatry</source> <volume>14</volume>: <fpage>696</fpage>–<lpage>704</lpage>.</citation>
</ref>
<ref id="bibr12-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coupland</surname><given-names>NJ</given-names></name>
<name><surname>Ogilvie</surname><given-names>CJ</given-names></name>
<name><surname>Hegadoren</surname><given-names>KM</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Decreased prefrontal myo-inositol in major depressive disorder</article-title>. <source>Biol Psychiatry</source> <volume>57</volume>: <fpage>1526</fpage>–<lpage>1534</lpage>.</citation>
</ref>
<ref id="bibr13-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crochemore</surname><given-names>C</given-names></name>
<name><surname>Lu</surname><given-names>J</given-names></name>
<name><surname>Wu</surname><given-names>Y</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation</article-title>. <source>Mol Psychiatry</source> <volume>10</volume>: <fpage>790</fpage>–<lpage>798</lpage>.</citation>
</ref>
<ref id="bibr14-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Czeh</surname><given-names>B</given-names></name>
<name><surname>Michaelis</surname><given-names>T</given-names></name>
<name><surname>Watanabe</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>98</volume>: <fpage>12796</fpage>–<lpage>12801</lpage>.</citation>
</ref>
<ref id="bibr15-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eker</surname><given-names>C</given-names></name>
<name><surname>Gonul</surname><given-names>AS</given-names></name>
</person-group> (<year>2010</year>) <article-title>Volumetric MRI studies of the hippocampus in major depressive disorder: Meanings of inconsistency and directions for future research</article-title>. <source>World J Biol Psychiatry</source> <volume>11</volume>: <fpage>19</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr16-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eker</surname><given-names>C</given-names></name>
<name><surname>Kitis</surname><given-names>O</given-names></name>
<name><surname>Taneli</surname><given-names>F</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Correlation of serum BDNF levels with hippocampal volumes in first episode, medication-free depressed patients</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source> <volume>260</volume>: <fpage>527</fpage>–<lpage>533</lpage>.</citation>
</ref>
<ref id="bibr17-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ende</surname><given-names>G</given-names></name>
<name><surname>Demirakca</surname><given-names>T</given-names></name>
<name><surname>Walter</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Subcortical and medial temporal MR-detectable metabolite abnormalities in unipolar major depression</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source> <volume>257</volume>: <fpage>36</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr18-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ende</surname><given-names>G</given-names></name>
<name><surname>Henn</surname><given-names>FA</given-names></name>
<name><surname>Braus</surname><given-names>DF</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>The hippocampus in patients treated with electroconvulsive therapy – A proton magnetic resonance spectroscopic imaging study</article-title>. <source>Arch Gen Psychiatry</source> <volume>57</volume>: <fpage>937</fpage>–<lpage>943</lpage>.</citation>
</ref>
<ref id="bibr19-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Farchione</surname><given-names>TR</given-names></name>
<name><surname>Moore</surname><given-names>GJ</given-names></name>
<name><surname>Rosenberg</surname><given-names>DR</given-names></name>
</person-group> (<year>2002</year>) <article-title>Proton magnetic resonance spectroscopic imaging in pediatric major depression</article-title>. <source>Biol Psychiatry</source> <volume>52</volume>: <fpage>86</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr20-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frodl</surname><given-names>T</given-names></name>
<name><surname>Jager</surname><given-names>M</given-names></name>
<name><surname>Smajstrlova</surname><given-names>I</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study</article-title>. <source>J Psychiatry Neurosci</source> <volume>33</volume>: <fpage>423</fpage>–<lpage>430</lpage>.</citation>
</ref>
<ref id="bibr21-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gonul</surname><given-names>AS</given-names></name>
<name><surname>Kitis</surname><given-names>O</given-names></name>
<name><surname>Ozan</surname><given-names>E</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>The effect of antidepressant treatment on N-acetyl aspartate levels of medial frontal cortex in drug-free depressed patients</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>30</volume>: <fpage>120</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr22-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gruber</surname><given-names>S</given-names></name>
<name><surname>Frey</surname><given-names>R</given-names></name>
<name><surname>Mlynarik</surname><given-names>V</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla</article-title>. <source>Invest Radiol</source> <volume>38</volume>: <fpage>403</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr23-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>W</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Effects of antidepressant treatment on N-acetyl aspartate and choline levels in the hippocampus and thalami of post-stroke depression patients: A study using 1H magnetic resonance spectroscopy</article-title>. <source>Psychiatry Res</source> <volume>182</volume>: <fpage>48</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr24-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jacobs</surname><given-names>BL</given-names></name>
<name><surname>van Praag</surname><given-names>H</given-names></name>
<name><surname>Gage</surname><given-names>FH</given-names></name>
</person-group> (<year>2000</year>) <article-title>Adult brain neurogenesis and psychiatry: a novel theory of depression</article-title>. <source>Mol Psychiatry</source> <volume>5</volume>: <fpage>262</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr25-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaymak</surname><given-names>SU</given-names></name>
<name><surname>Demir</surname><given-names>B</given-names></name>
<name><surname>Oguz</surname><given-names>KK</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Antidepressant effect detected on proton magnetic resonance spectroscopy in drug-naive female patients with first-episode major depression</article-title>. <source>Psychiatry Clin Neurosci</source> <volume>63</volume>: <fpage>350</fpage>–<lpage>356</lpage>.</citation>
</ref>
<ref id="bibr26-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>SH</given-names></name>
<name><surname>Evans</surname><given-names>KR</given-names></name>
<name><surname>Kruger</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression</article-title>. <source>Am J Psychiatry</source> <volume>158</volume>: <fpage>899</fpage>–<lpage>905</lpage>.</citation>
</ref>
<ref id="bibr27-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koolschijn</surname><given-names>PC</given-names></name>
<name><surname>van Haren</surname><given-names>NE</given-names></name>
<name><surname>Lensvelt-Mulders</surname><given-names>GJ</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies</article-title>. <source>Hum Brain Mapp</source> <volume>30</volume>: <fpage>3719</fpage>–<lpage>3735</lpage>.</citation>
</ref>
<ref id="bibr28-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krishnan</surname><given-names>V</given-names></name>
<name><surname>Nestler</surname><given-names>EJ</given-names></name>
</person-group> (<year>2008</year>) <article-title>The molecular neurobiology of depression</article-title>. <source>Nature</source> <volume>455</volume>: <fpage>894</fpage>–<lpage>902</lpage>.</citation>
</ref>
<ref id="bibr29-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>A</given-names></name>
<name><surname>Thomas</surname><given-names>A</given-names></name>
<name><surname>Lavretsky</surname><given-names>H</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy</article-title>. <source>Am J Psychiatry</source> <volume>159</volume>: <fpage>630</fpage>–<lpage>636</lpage>.</citation>
</ref>
<ref id="bibr30-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kusumakar</surname><given-names>V</given-names></name>
<name><surname>MacMaster</surname><given-names>FP</given-names></name>
<name><surname>Gates</surname><given-names>L</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Left medial temporal cytosolic choline in early onset depression</article-title>. <source>Can J Psychiatry</source> <volume>46</volume>: <fpage>959</fpage>–<lpage>964</lpage>.</citation>
</ref>
<ref id="bibr31-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lupien</surname><given-names>SJ</given-names></name>
<name><surname>de Leon</surname><given-names>M</given-names></name>
<name><surname>de Santi</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Cortisol levels during human aging predict hippocampal atrophy and memory deficits</article-title>. <source>Nat Neurosci</source> <volume>1</volume>: <fpage>69</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr32-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Magarinos</surname><given-names>AM</given-names></name>
<name><surname>Deslandes</surname><given-names>A</given-names></name>
<name><surname>McEwen</surname><given-names>BS</given-names></name>
</person-group> (<year>1999</year>) <article-title>Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress</article-title>. <source>Eur J Pharmacol</source> <volume>371</volume>: <fpage>113</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr33-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malberg</surname><given-names>JE</given-names></name>
<name><surname>Eisch</surname><given-names>AJ</given-names></name>
<name><surname>Nestler</surname><given-names>EJ</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus</article-title>. <source>J Neurosci</source> <volume>20</volume>: <fpage>9104</fpage>–<lpage>9110</lpage>.</citation>
</ref>
<ref id="bibr34-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malykhin</surname><given-names>NV</given-names></name>
<name><surname>Carter</surname><given-names>R</given-names></name>
<name><surname>Seres</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment</article-title>. <source>J Psychiatry Neurosci</source> <volume>35</volume>: <fpage>337</fpage>–<lpage>343</lpage>.</citation>
</ref>
<ref id="bibr35-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manev</surname><given-names>H</given-names></name>
<name><surname>Uz</surname><given-names>T</given-names></name>
<name><surname>Smalheiser</surname><given-names>NR</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Antidepressants alter cell proliferation in the adult brain in vivo and in neural cultures in vitro</article-title>. <source>Eur J Pharmacol</source> <volume>411</volume>: <fpage>67</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr36-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McLaughlin</surname><given-names>KJ</given-names></name>
<name><surname>Gomez</surname><given-names>JL</given-names></name>
<name><surname>Baran</surname><given-names>SE</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>The effects of chronic stress on hippocampal morphology and function: an evaluation of chronic restraint paradigms</article-title>. <source>Brain Res</source> <volume>1161</volume>: <fpage>56</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr37-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mervaala</surname><given-names>E</given-names></name>
<name><surname>Fohr</surname><given-names>J</given-names></name>
<name><surname>Kononen</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Quantitative MRI of the hippocampus and amygdala in severe depression</article-title>. <source>Psychol Med</source> <volume>30</volume>: <fpage>117</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr38-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Michael</surname><given-names>N</given-names></name>
<name><surname>Erfurth</surname><given-names>A</given-names></name>
<name><surname>Ohrmann</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression</article-title>. <source>Neuropsychopharmacology</source> <volume>28</volume>: <fpage>720</fpage>–<lpage>725</lpage>.</citation>
</ref>
<ref id="bibr39-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Milne</surname><given-names>A</given-names></name>
<name><surname>MacQueen</surname><given-names>GM</given-names></name>
<name><surname>Yucel</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Hippocampal metabolic abnormalities at first onset and with recurrent episodes of a major depressive disorder: A proton magnetic resonance spectroscopy study</article-title>. <source>Neuroimage</source> <volume>47</volume>: <fpage>36</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr40-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mirza</surname><given-names>Y</given-names></name>
<name><surname>Tang</surname><given-names>J</given-names></name>
<name><surname>Russell</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <volume>43</volume>: <fpage>341</fpage>–<lpage>348</lpage>.</citation>
</ref>
<ref id="bibr41-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moore</surname><given-names>GJ</given-names></name>
<name><surname>Bebchuk</surname><given-names>JM</given-names></name>
<name><surname>Hasanat</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects?</article-title> <source>Biol Psychiatry</source> <volume>48</volume>: <fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr42-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nestler</surname><given-names>EJ</given-names></name>
<name><surname>Barrot</surname><given-names>M</given-names></name>
<name><surname>DiLeone</surname><given-names>RJ</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Neurobiology of depression</article-title>. <source>Neuron</source> <volume>34</volume>: <fpage>13</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr43-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neylan</surname><given-names>TC</given-names></name>
<name><surname>Schuff</surname><given-names>N</given-names></name>
<name><surname>Lenoci</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Cortisol levels are positively correlated with hippocampal N-acetylaspartate</article-title>. <source>Biol Psychiatry</source> <volume>54</volume>: <fpage>1118</fpage>–<lpage>1121</lpage>.</citation>
</ref>
<ref id="bibr44-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Brien</surname><given-names>JT</given-names></name>
<name><surname>Lloyd</surname><given-names>A</given-names></name>
<name><surname>McKeith</surname><given-names>I</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects</article-title>. <source>Am J Psychiatry</source> <volume>161</volume>: <fpage>2081</fpage>–<lpage>2090</lpage>.</citation>
</ref>
<ref id="bibr45-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olvera</surname><given-names>RL</given-names></name>
<name><surname>Caetano</surname><given-names>SC</given-names></name>
<name><surname>Stanley</surname><given-names>JA</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Reduced medial prefrontal N-Acetyl-Aspartate levels in pediatric major depressive disorder: A multi-voxel in vivo1H spectroscopy study</article-title>. <source>Psychiatry Res</source> <volume>184</volume>: <fpage>71</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr46-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perera</surname><given-names>TD</given-names></name>
<name><surname>Coplan</surname><given-names>JD</given-names></name>
<name><surname>Lisanby</surname><given-names>SH</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates</article-title>. <source>J Neurosci</source> <volume>27</volume>: <fpage>4894</fpage>–<lpage>4901</lpage>.</citation>
</ref>
<ref id="bibr47-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rajkowska</surname><given-names>G</given-names></name>
</person-group> (<year>2003</year>) <article-title>Depression: What we can learn from postmortem studies</article-title>. <source>Neuroscientist</source> <volume>9</volume>: <fpage>273</fpage>–<lpage>284</lpage>.</citation>
</ref>
<ref id="bibr48-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ravnkilde</surname><given-names>B</given-names></name>
<name><surname>Videbech</surname><given-names>P</given-names></name>
<name><surname>Clemmensen</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Cognitive deficits in major depression</article-title>. <source>Scand J Psychol</source> <volume>43</volume>: <fpage>239</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr49-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sala</surname><given-names>M</given-names></name>
<name><surname>Perez</surname><given-names>J</given-names></name>
<name><surname>Soloff</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Stress and hippocampal abnormalities in psychiatric disorders</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>14</volume>: <fpage>393</fpage>–<lpage>405</lpage>.</citation>
</ref>
<ref id="bibr50-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sapolsky</surname><given-names>RM</given-names></name>
</person-group> (<year>2000a</year>) <article-title>Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders</article-title>. <source>Arch Gen Psychiatry</source> <volume>57</volume>: <fpage>925</fpage>–<lpage>935</lpage>.</citation>
</ref>
<ref id="bibr51-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sapolsky</surname><given-names>RM</given-names></name>
</person-group> (<year>2000b</year>) <article-title>The possibility of neurotoxicity in the hippocampus in major depression: A primer on neuron death</article-title>. <source>Biol Psychiatry</source> <volume>48</volume>: <fpage>755</fpage>–<lpage>765</lpage>.</citation>
</ref>
<ref id="bibr52-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saxena</surname><given-names>S</given-names></name>
<name><surname>Brody</surname><given-names>AL</given-names></name>
<name><surname>Ho</surname><given-names>ML</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently</article-title>. <source>Biol Psychiatry</source> <volume>50</volume>: <fpage>159</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr53-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steingard</surname><given-names>RJ</given-names></name>
<name><surname>Yurgelun-Todd</surname><given-names>DA</given-names></name>
<name><surname>Hennen</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy</article-title>. <source>Biol Psychiatry</source> <volume>48</volume>: <fpage>1053</fpage>–<lpage>1061</lpage>.</citation>
</ref>
<ref id="bibr54-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stockmeier</surname><given-names>CA</given-names></name>
<name><surname>Mahajan</surname><given-names>GJ</given-names></name>
<name><surname>Konick</surname><given-names>LC</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Cellular changes in the postmortem hippocampus in major depression</article-title>. <source>Biol Psychiatry</source> <volume>56</volume>: <fpage>640</fpage>–<lpage>650</lpage>.</citation>
</ref>
<ref id="bibr55-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>M</given-names></name>
<name><surname>Murphy</surname><given-names>SE</given-names></name>
<name><surname>Selvaraj</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy</article-title>. <source>J Psychopharmacol</source> <volume>22</volume>: <fpage>473</fpage>–<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr56-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Urenjak</surname><given-names>J</given-names></name>
<name><surname>Williams</surname><given-names>SR</given-names></name>
<name><surname>Gadian</surname><given-names>DG</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types</article-title>. <source>J Neurosci</source> <volume>13</volume>: <fpage>981</fpage>–<lpage>989</lpage>.</citation>
</ref>
<ref id="bibr57-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Videbech</surname><given-names>P</given-names></name>
<name><surname>Ravnkilde</surname><given-names>B</given-names></name>
</person-group> (<year>2004</year>) <article-title>Hippocampal volume and depression: a meta-analysis of MRI studies</article-title>. <source>Am J Psychiatry</source> <volume>161</volume>: <fpage>1957</fpage>–<lpage>1966</lpage>.</citation>
</ref>
<ref id="bibr58-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Videbech</surname><given-names>P</given-names></name>
<name><surname>Ravnkilde</surname><given-names>B</given-names></name>
<name><surname>Pedersen</surname><given-names>TH</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>The Danish PET/depression project: clinical symptoms and cerebral blood flow. A regions-of-interest analysis</article-title>. <source>Acta Psychiatr Scand</source> <volume>106</volume>: <fpage>35</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr59-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vythilingam</surname><given-names>M</given-names></name>
<name><surname>Charles</surname><given-names>HC</given-names></name>
<name><surname>Tupler</surname><given-names>LA</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Focal and lateralized subcortical abnormalities in unipolar major depressive disorder: An automated multivoxel proton magnetic resonance spectroscopy study</article-title>. <source>Biol Psychiatry</source> <volume>54</volume>: <fpage>744</fpage>–<lpage>750</lpage>.</citation>
</ref>
<ref id="bibr60-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vythilingam</surname><given-names>M</given-names></name>
<name><surname>Vermetten</surname><given-names>E</given-names></name>
<name><surname>Anderson</surname><given-names>GM</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment</article-title>. <source>Biol Psychiatry</source> <volume>56</volume>: <fpage>101</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr61-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>JW</given-names></name>
<name><surname>David</surname><given-names>DJ</given-names></name>
<name><surname>Monckton</surname><given-names>JE</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells</article-title>. <source>J Neurosci</source> <volume>28</volume>: <fpage>1374</fpage>–<lpage>1384</lpage>.</citation>
</ref>
<ref id="bibr62-0269881112450781">
<citation citation-type="book">
<collab>World Health Organization</collab> (<year>2001</year>) <source>The World Health Report: 2001. Mental Health: New Understanding</source>, <publisher-loc>New Hope</publisher-loc>: <publisher-name>World Health Organization</publisher-name>.</citation>
</ref>
<ref id="bibr63-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yau</surname><given-names>JLW</given-names></name>
<name><surname>Hibberd</surname><given-names>C</given-names></name>
<name><surname>Noble</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats</article-title>. <source>Mol Brain Res</source> <volume>106</volume>: <fpage>117</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr64-0269881112450781">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yildiz-Yesiloglu</surname><given-names>A</given-names></name>
<name><surname>Ankerst</surname><given-names>DP</given-names></name>
</person-group> (<year>2006</year>) <article-title>Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis</article-title>. <source>Psychiatry Res</source> <volume>147</volume>: <fpage>1</fpage>–<lpage>25</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>